Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Bazedoxifene (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 28 Feb 2018 Planned End Date changed from 1 Oct 2017 to 7 Nov 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Jul 2017 to 11 Apr 2018.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.